

# INVESTOR LETTER

---

## JULY 2021

### We will reach the market together

”

As I have gotten to know both the organization and the board, I have seen opportunities to make even greater use of the combined expertise.

Johan Folkunger, CEO of SpectraCure

The Board and management of SpectraCure have received an injection of new blood and new, good foundations for a continued joint work has been created.

- The work of the Board and interaction between the Board and the management has been intensified in recent months. Both Homer Pien and Johan Folkunger have settled in well and their skills, drive and personalities contribute strongly to our Board work. I am also pleased to see how Johan has already engaged the Board in the strategic work and to some extent also in the operational work. I am not surprised, I just note that the two recruitments have turned out just as good as the Board and the main owners wished, says Ingemar Kihlström the Chairman of the Board.
- Developing a new unique treatment system with the potential that SpectraCure's system has, is impressive and can make a difference for cancer care in general but above all for the large group of prostate cancer patients. Everyone in the company, both employees, management and Board have a responsibility to unleash this potential and I am impressed and pleased to see such strong commitment and drive in all areas of the company. As I have gotten to know the organization and the Board, I have seen opportunities to make even greater impact with the combined expertises – something which I see as extremely important for us, to work together and move the company forward in the best way, comments Johan Folkunger.



Johan Folkunger



## Brief fact about Homer Pien, new board member of SpectraCure.

*Homer Pien was most recently SVP and Chief Scientific Officer for the Precision Diagnosis cluster of businesses, and prior to that Chief Technology Officer for Imaging System, at Philips. Before joining Philips in 2012, he was in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School, where he led the Laboratory for Medical Imaging and Computations. Homer has also worked for two start-ups, one of which was a biotech company he co-founded and served as CEO before the company was acquired. Earlier in his career Homer was at MIT Lincoln Lab and Draper Lab. Homer has a PhD in computer science from Northeastern University (Boston, MA), and MS Management from Massachusetts Institute of Technology (Cambridge, MA).*

## Board member with good track record

### How did you become interested in SpectraCure?

When I first started to work with Massachusetts General Hospital more than 20 years ago, I was fortunate enough to be working with incredible researchers who were engaged in photodynamic therapy (PDT). I was very intrigued by PDT's ability to provide localized, focused, and highly targeted treatments. Since then, I've kept track of developments in PDT, and was aware of SpectraCure's use of PDT to target prostate cancer. When my colleague from Philips, Johan Folkunger, accepted the position of CEO of SpectraCure and asked me to consider being involved, I eagerly jumped at the opportunity.

### Tell us a bit of your professional background.

I have always worked at the interface between technology and medicine. For years I worked on computer vision and image processing approaches to enhance radiologic images, especially focusing on developing robust segmentation models for segmenting regions of the brain using MRI. Then at Mass General I was given the opportunity to use novel computing hardware to create CT images in new ways – an approach called iterative reconstructions. And most recently at Philips, I was overseeing projects which both improved how we obtain radiologic images, as well as novel ways of combining imaging with other diagnostic modalities using artificial intelligence approaches – an area called integrated diagnoses.

### What specific experience and knowledge would you say you bring to SpectraCure?

In a sense, I see my strength as being able to bridge clinical knowledge, technology solutions, and business – that is, being able to translate scientific developments that solve a clinical need into products and business opportunities.

**"SpectraCure has done terrific science; I see part of my role as supporting the transition of science to business opportunities, making sure the scientific developments fit into the broader context of a sound business strategy that developments and marketing/sales work hand-in-hand..."**

SpectraCure has done terrific science; I see part of my role as supporting the transition of science to business opportunities, making sure the scientific developments fit into the broader context of a sound business strategy, that developments and marketing/sales work hand-in-hand, that regulatory and reimbursement aspects are thought about, that we develop

the infrastructure to enable us to scale, and capture larger opportunities with the platform we're developing.

### How would you describe yourself as a person?

I would characterize myself in a couple of different ways. I am highly curious, and I enjoy digging deeply into unanswered questions. I am also practical – I think about the implications of an advancement, not just scientific knowledge purely for the sake of knowledge. Lastly, I think I'm a puzzle solver – I like jiggling the pieces until they fit into a broader picture, which to me is how we solve problems that address an unmet clinical need.

## An important addition to the team

The product development team has been strengthened with Rebecca Sahlén, MSc. in medical technology. Rebecca is responsible for the technical documentation and works with product development, supplier contacts and she supports the work in the clinical study.

- With previous experience from the defense industry, which has similar requirements on quality and documentation standards as medical technology, Rebecca is an important addition to the team and the further product development, says Johannes Swartling, CTO of SpectraCure.
- That SpectraCure is in an exciting phase is evident in my daily work. By optimizing documentation and processes, I work to improve quality and efficiency. I benefit greatly from my previous experience of serial production and work with quality management systems, comments Rebecca Sahlén.



## Financial calendar

Interim Report Q2  
25 August

Interim Report Q3  
16 November

Interim Report Q4  
17 February

Happy summer  
wishes  
SpectraCure

Follow us on social media



[spectracure.com](https://spectracure.com)